Androgens induce increases in intracellular calcium via a G protein-coupled receptor in LNCaP prostate cancer cells

J Androl. 2006 Sep-Oct;27(5):671-8. doi: 10.2164/jandrol.106.000554. Epub 2006 May 25.

Abstract

The receptor mechanism of testosterone-induced nongenomic Ca2+ signaling in prostate cancer cells is poorly understood. In this study we investigated androgen-induced intracellular Ca2+ increases in LNCaP human prostate cancer cells with Fura-2 as a Ca2+ probe. 5alpha-dihydrotestosterone (DHT) produced fast and transient increases in intracellular Ca2+ in LNCaP cells in a concentration-dependent manner. These effects were abolished by extracellular Ca2+ removal or pretreatment with L-type Ca2+ channel inhibitors (nifedipine, verapamil, and diltiazem). Pretreatment with endoplasmic reticulum ryanodine receptor blocker (procaine) or phospholipase C inhibitor (neomycin sulfate) did not alter DHT-induced Ca2+ influx. The concentration of Ca2+ was also increased by impermeable testosterone conjugated to bovine serum albumin. Neither an antagonist of intracellular androgen receptors (cyproterone acetate) nor a protein synthesis inhibitor (cycloheximide) affected this fast Ca2+ influx. Furthermore, the effect of DHT was abolished in cells incubated with a G protein inhibitor (pertussis toxin) and a nonhydrolyzable analog of guanosine triphosphate (guanosine 5-[beta-thio]disphosphate) but not in cells incubated with the tyrosine kinase inhibitor genistein. These results indicate that androgens induced an L-type calcium channel-dependent intracellular Ca2+ increase in LNCaP prostate cancer cells. The rapid responses triggered by DHT did not appear to be mediated through classic intracellular androgen receptors, c-Src kinase-androgen receptor complex, or sex hormone-binding globulin but through a G protein-coupled receptor in LNCaP prostate cancer cells. These results may provide a new explanation for progression of prostate cancer.

MeSH terms

  • Androgens / pharmacology*
  • Calcium / metabolism*
  • Calcium Channel Blockers / pharmacology
  • Calcium Channels, L-Type / drug effects
  • Calcium Signaling / drug effects*
  • Cell Line, Tumor
  • Cyproterone Acetate / pharmacology
  • Dihydrotestosterone / pharmacology*
  • Egtazic Acid / pharmacology
  • Humans
  • Male
  • Prostatic Neoplasms / physiopathology*
  • Receptors, G-Protein-Coupled / physiology*

Substances

  • Androgens
  • Calcium Channel Blockers
  • Calcium Channels, L-Type
  • Receptors, G-Protein-Coupled
  • Dihydrotestosterone
  • Cyproterone Acetate
  • Egtazic Acid
  • Calcium